News

As per terms of the deal, BTG is expected to gain TheraSphere, which is the sole targeted liver cancer therapy product of Targeted Therapies business that is manufactured

A total of 120 individuals are expected to be included in the double-blind, multicenter study designed to assess the safety and efficacy profile of UC1010. Umecrine Mood CEO

The application covers the use of Abraxane and gemcitabine combination therapy for the front line treatment of patients with advanced pancreatic cancer. In April 2013, the European Medicines

The certificate is granted for the company’s proprietary vaccines, Haidian district bulk production plants, and Changping filing and packaging facility. Sinovac chairman, president and CEO Dr. Weidong YIN

Under the partnership, the college will support the development of new and commercial delivery forms of low dose Naltrexone in the form of oral capsules and tablets and

The company has also upgraded its systems to provide current good manufacturer practices (cGMP)-level quality in its home delivery pharmacy in Sioux Falls, South Dakota to prevent deviations,

Selection of the third cardiovascular target by Servier marks the first milestone for miRagen under the collaboration. Servier chief executive officer Dr. Jean-Philippe Seta said, "Micro-RNA is now

OMS824 is developed to selectively inhibit phosphodiesterase 10 enzyme that is expressed in areas of the brain associated with an array of diseases affecting cognition, such as Huntington’s

The late stage products to be submitted for approval include drugs targeting varying diseases such as hepatitis C, immune diseases and schizophrenia, and vaccines for flu, rabies and